Kansas PKD Research and Translation Core Center - Administrative Core

堪萨斯 PKD 研究和翻译核心中心 - 行政核心

• 批准号: 10892365
• 负责人: JAMES P CALVET
• 金额: $ 6.42万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-15 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10892365
• 关键词: Abnormal Cell; Advisory Committees; Advocate; Area; Autosomal Dominant Polycystic Kidney; Biochemistry; Biocompatible Materials; Biological Markers; Biomedical Research; Cancer Center; Cell Proliferation; Cell model; Cellular biology; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Communication; Communities; Cyst; Decision Making; Development; Disease; Disease Progression; Education; Educational workshop; Effectiveness; Ensure; Evaluation; FDA approved; Fluids and Secretions; Funding; Genetic Models; Grant; Growth; Informatics; Institution; Kansas; Malignant Neoplasms; Mission; National Institute of Diabetes and Digestive and Kidney Diseases; Pathway interactions; Patient-Focused Outcomes; Patients; Play; Reagent; Recording of previous events; Research; Research Methodology; Research Personnel; Research Project Grants; Research Support; Resource Sharing; Resources; Review Committee; Rodent Model; Role; Scientist; Services; Signal Transduction; Site; Techniques; Technology; Testing; Translational Research; Translations; Work; biomarker discovery; clinical development; clinical translation; drug testing; falls; improved; innovation; member; novel; patient oriented; programs; recruit; summer student; symposium; therapeutic target; tolvaptan

Project Summary - Administrative Core The mission of the Kansas PKD Research and Translation Core Center (RTCC) is to promote PKD research by providing essential reagents, biomaterials, and service to the PKD research community for the advancement of our understanding of disease mechanisms, the discovery of biomarkers and therapeutic targets and the development of clinical trials to improve patient outcomes. The mission of the Center is based on research at Kansas that discovered and characterized many of the key pathways now being considered for PKD therapy, and that ultimately led to the development of Tolvaptan as the first FDA approved therapy for ADPKD. The Kansas PKD RTCC has created three biomedical research cores to support the research programs of external core users in the PKD Research Consortium and the greater PKD research community. These cores are: Core 1. Biomarkers, Biomaterials, and Cellular Models (Darren Wallace, Director), Core 2. Rodent Models & Drug Testing (Pamela Tran and Stephen Parnell, Co-Directors), and Core 3. Clinical Research (Alan Yu, Director). The Administrative Core will be responsible for setting the overall scientific direction of the Kansas PKD Center, overseeing core activities, and for prioritizing the distribution of resources to each of the cores. The Administrative Core will also be responsible for organizing a variety of educational enrichment activities, including a Summer Student Enrichment Program, PKD research methods workshops, professional development sessions, Research Methods and Advanced Technologies Program, research seminars, retreats, patient- oriented activities, and will work with the Central Coordinating Site (CCS) on the annual symposium. The Administrative Core has an Internal Advisory Committee (IAC) comprised of the center directors and core directors and established KUMC scientists outside the PKD field who will bring their expertise to the committee, plus a representative from the PKD patient community to serve as a patient advocate. All PKD Core Center activities will be regularly reviewed and evaluated by the Internal Advisory Committee for communication to the CCS Steering Committee, the External Evaluation Panel (EEP), and NIDDK. The Administrative Core will support the recruitment of new investigators into the PKD field through various mechanisms including an innovative internal pilot grant program in partnership with the KU Cancer Center to support research projects exploring the relationship between PKD and cancer. Finally, the Administrative Core will work to promote strong interactions between the Kansas PKD Center and the institution by interfacing its activities with other programs, centers, and institutes at KUMC, and by integrating the biomedical research cores with existing institutional shared resource centers and biomedical cores; and will encourage open and frequent communication with the CCS and with the other national PKD RTCCs to maximize the benefits offered by our unique, high-value core services to the national PKD community.

项目摘要-行政核心 堪萨斯PKD研究和翻译核心中心（RTCC）的使命是促进PKD 通过为PKD研究社区提供必要的试剂，生物材料和服务， 推进我们对疾病机制的理解，发现生物标志物和治疗靶点 以及临床试验的发展，以改善患者的治疗效果。该中心的使命基于 在堪萨斯的一项研究发现并描述了许多现在被认为是PKD的关键途径 这最终导致了托伐普坦的开发，成为FDA批准的第一种ADPKD治疗方法。 堪萨斯PKD RTCC已经创建了三个生物医学研究核心，以支持以下研究项目： PKD研究联盟和更大的PKD研究社区的外部核心用户。这些核 核心：1。生物标志物，生物材料和细胞模型（Darren Wallace，主任），核心2。啮齿动物模型 和药物测试（帕梅拉陈和斯蒂芬帕内尔，联合董事），和核心3。临床研究（Alan Yu， 主任）。行政核心将负责制定堪萨斯的总体科学方向 PKD中心，监督核心活动，并优先分配资源到每个核心。的 行政核心还将负责组织各种教育充实活动，包括 暑期学生充实计划，PKD研究方法研讨会，专业发展 会议，研究方法和先进技术计划，研究研讨会，务虚会，病人- 该中心将与中央协调中心（CCS）合作举办年度专题讨论会。的 行政核心有一个内部咨询委员会（IAC）组成的中心主任和核心 董事和建立KUMC科学家以外的PKD领域谁将带来他们的专业知识，委员会， 加上PKD患者社区的一名代表，作为患者的倡导者。所有PKD核心中心 内部咨询委员会将定期审查和评估活动， CCS指导委员会、外部评估小组（EEP）和NIDDK。行政核心将支持 通过各种机制征聘新的调查人员进入PKD领域，包括创新的 与KU癌症中心合作的内部试点赠款计划，以支持探索 PKD与癌症的关系最后，行政核心将努力促进强有力的互动 堪萨斯PKD中心和机构之间的接口与其他计划，中心， KUMC的研究所，并将生物医学研究核心与现有的机构共享资源相结合， 中心和生物医学核心;并将鼓励与CCS和 其他国家PKD RTCC，以最大限度地发挥我们独特的，高价值的核心服务提供的好处， 全国PKD社区。